At present, anti-vascular endothelial growth factor (anti-VEGF) therapy has enabled extraordinary improvements in wet AMD; however, effective treatments for dry AMD are not yet available [4, 5]. The gene discussed is VEGFA; the disease is dry age related macular degeneration.